MabCure Signs Research Agreement (OTC:MBCI)

MabCure N.V., a subsidiary of MabCure Inc (OTC:MBCI) today announced that they have signed a research agreement with AZ Sint Lucas Hospital in Belgium to conduct preclinical research on its monoclonal antibodies against different cancers. Currently, the company’s monoclonal antibodies for the diagnosis of ovarian cancer, prostrate cancer, and colorectal cancer are aimed at diagnosing early stage disease in physiological samples such as urine and serum. The Sint Lucas General Hospital in Bruges is an independent hospital with emphasis on advanced patient care, active clinical research and participation in multi-center clinical trials.

MabCure Inc is a leading biotechnology company which is working hard to treat cancer. The Company has proprietary technology for the creation of unique and highly specific monoclonal antibodies also known as MAbs, which will be developed and used as diagnostic tools, imaging agents, and drugs for the treatment of lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. As per the agreement studies have already begun at the AZ Sint Lucas Hospital, however all scientific results will remain with MabCure Inc.

MabCure CEO, Dr. Amnon Gonenne has said that they are happy with the agreement and if the preclinical research works than it would provide them more information that will help them to diagnose everything that goes to surgery. He further stated that patients with at-risk melanoma normally remove their moles prophylactically and currently there is no method to determine if the removed moles harbor early stage melanoma or not. With Mabs they will be able to do the diagnosis of early stage melanoma as it is a highly lethal disease.